{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:48:53Z","timestamp":1771627733719,"version":"3.50.1"},"reference-count":13,"publisher":"American Physiological Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Physiology-Endocrinology and Metabolism"],"published-print":{"date-parts":[[1993,4,1]]},"abstract":"<jats:p>Amylin and calcitonin gene-related peptide (CGRP) inhibited insulin-stimulated 2-deoxyglucose uptake in L6 myocytes and isolated soleus muscle. Both peptides were maximally active at 10 pM in L6 cells and inhibited insulin action by 40-50%. In soleus muscle amylin and CGRP inhibited insulin-stimulated uptake by 65-85%. Amylin competed with 125I-CGRP for binding to L6 cells but with 100-fold lower potency than CGRP. Occupancy of the CGRP receptor in L6 cells is coupled to adenylyl cyclase. Amylin increased the cellular content of adenosine 3',5'-cyclic monophosphate (cAMP), but consistent with binding, amylin was 100-fold less potent than CGRP. In soleus muscle, 100 nM amylin, which maximally inhibited 2-deoxyglucose uptake, had no effect cAMP content, whereas CGRP at the same concentration increased cAMP by 50%. The effect of CGRP on cAMP levels was completely suppressed by the competitive antagonist, CGRP-(8-37). In contrast, the suppression of insulin-stimulated glycogen synthesis or 2-deoxyglucose uptake by amylin was unaffected by 1 microM CGRP-(8-37). Our results demonstrate that the inhibition of insulin-stimulated glucose transport by amylin is independent of cAMP and may be mediated by a unique receptor that is distinct from the adenylyl cyclase-coupled CGRP receptor.<\/jats:p>","DOI":"10.1152\/ajpendo.1993.264.4.e606","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T23:38:48Z","timestamp":1513899528000},"page":"E606-E613","source":"Crossref","is-referenced-by-count":14,"title":["Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor"],"prefix":"10.1152","volume":"264","author":[{"given":"D. K.","family":"Kreutter","sequence":"first","affiliation":[{"name":"Department of Metabolic Diseases, Pfizer Inc., Groton, Connecticut06340."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Orena","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Pfizer Inc., Groton, Connecticut06340."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Torchia","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Pfizer Inc., Groton, Connecticut06340."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. G.","family":"Contillo","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Pfizer Inc., Groton, Connecticut06340."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. C.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Pfizer Inc., Groton, Connecticut06340."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. W.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Pfizer Inc., Groton, Connecticut06340."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"24","reference":[{"key":"p_1","first-page":"189","volume":"310","author":"Barakat A.","year":"1990","journal-title":"Ser. III Sci. Vie"},{"key":"p_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(89)81467-X"},{"key":"p_3","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401050"},{"key":"p_4","first-page":"487","volume":"136","author":"Brain S. D.","journal-title":"Am. J. Puthol."},{"key":"p_5","doi-asserted-by":"publisher","DOI":"10.2337\/diab.39.6.752"},{"key":"p_7","first-page":"E331","author":"Chiba T.","year":"1989","journal-title":"Metub. 19)"},{"key":"p_8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)90825-7"},{"key":"p_9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.20.7763"},{"key":"p_10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.23.8628"},{"key":"p_11","doi-asserted-by":"publisher","DOI":"10.1042\/bj1860525"},{"key":"p_12","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)92391-7"},{"key":"p_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-3565(25)12587-1","volume":"254","author":"Dennis T.","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"p_14","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(90)90352-N"}],"container-title":["American Journal of Physiology-Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.physiology.org\/doi\/pdf\/10.1152\/ajpendo.1993.264.4.E606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T03:54:06Z","timestamp":1751169246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.physiology.org\/doi\/10.1152\/ajpendo.1993.264.4.E606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,4,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1993,4,1]]}},"alternative-id":["10.1152\/ajpendo.1993.264.4.E606"],"URL":"https:\/\/doi.org\/10.1152\/ajpendo.1993.264.4.e606","relation":{},"ISSN":["0193-1849","1522-1555"],"issn-type":[{"value":"0193-1849","type":"print"},{"value":"1522-1555","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,4,1]]}}}